CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765)
China
· Delayed Price · Currency is CNY 22.41
-0.42 (-1.84%)
Sep 9, 2024, 1:54 PM CST
CSPC Innovation Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 2,074 | 2,450 | 2,571 | 1,790 | 1,289 | 1,223 | Upgrade
|
| Other Revenue | 55.32 | 51.35 | 55.25 | 60.14 | 28.2 | 33.25 | Upgrade
|
| Revenue | 2,129 | 2,502 | 2,626 | 1,850 | 1,317 | 1,257 | Upgrade
|
| Revenue Growth (YoY) | -21.98% | -4.75% | 42.00% | 40.40% | 4.85% | 1.32% | Upgrade
|
| Cost of Revenue | 1,208 | 1,369 | 1,493 | 1,043 | 584.91 | 613.27 | Upgrade
|
| Gross Profit | 920.81 | 1,133 | 1,133 | 807.09 | 732.5 | 643.24 | Upgrade
|
| Selling, General & Admin | 249.92 | 290.49 | 312.29 | 323.91 | 374.09 | 328.3 | Upgrade
|
| Research & Development | -1.32 | 46.54 | 46.3 | 26.5 | 14.05 | 13.05 | Upgrade
|
| Other Operating Expenses | 29.22 | 26.28 | 19.92 | 15.75 | 1.63 | 17.03 | Upgrade
|
| Operating Expenses | 277.48 | 358.47 | 386.31 | 372.19 | 388.36 | 357.52 | Upgrade
|
| Operating Income | 643.33 | 774.26 | 747.14 | 434.9 | 344.14 | 285.72 | Upgrade
|
| Interest Expense | - | -0.36 | -0.22 | -2.83 | - | -1.5 | Upgrade
|
| Interest & Investment Income | 83.9 | 78.48 | 49.57 | 45.37 | 34.02 | 20.35 | Upgrade
|
| Currency Exchange Gain (Loss) | 16.99 | 25.52 | 55.21 | -7.07 | -19.66 | 5.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.88 | -0.27 | -0.98 | -1.08 | 5.21 | -0.51 | Upgrade
|
| EBT Excluding Unusual Items | 737.6 | 877.64 | 850.72 | 469.29 | 363.71 | 309.39 | Upgrade
|
| Impairment of Goodwill | - | - | - | -3.47 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 3.59 | 1.94 | 3.89 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.64 | 0.33 | 1.61 | 0.38 | -0.43 | 0.22 | Upgrade
|
| Asset Writedown | -2.67 | -2.15 | -6.17 | -10.1 | - | -2.21 | Upgrade
|
| Other Unusual Items | 19.75 | 15.97 | 5.22 | 18.3 | - | 23.89 | Upgrade
|
| Pretax Income | 755.36 | 891.79 | 851.37 | 477.99 | 365.22 | 335.17 | Upgrade
|
| Income Tax Expense | 106.32 | 136.47 | 124.76 | 85.29 | 65.51 | 61.64 | Upgrade
|
| Earnings From Continuing Operations | 649.04 | 755.32 | 726.61 | 392.7 | 299.71 | 273.53 | Upgrade
|
| Minority Interest in Earnings | -21.35 | 0.24 | -0.33 | 0.53 | 0.12 | -0.33 | Upgrade
|
| Net Income | 627.69 | 755.56 | 726.28 | 393.23 | 299.84 | 273.2 | Upgrade
|
| Net Income to Common | 627.69 | 755.56 | 726.28 | 393.23 | 299.84 | 273.2 | Upgrade
|
| Net Income Growth | -4.80% | 4.03% | 84.70% | 31.15% | 9.75% | 22.05% | Upgrade
|
| Shares Outstanding (Basic) | 1,376 | 1,388 | 1,337 | 1,337 | 1,178 | 1,105 | Upgrade
|
| Shares Outstanding (Diluted) | 1,376 | 1,388 | 1,337 | 1,337 | 1,178 | 1,105 | Upgrade
|
| Shares Change (YoY) | -4.73% | 3.82% | -0.02% | 13.53% | 6.56% | 24.77% | Upgrade
|
| EPS (Basic) | 0.46 | 0.54 | 0.54 | 0.29 | 0.25 | 0.25 | Upgrade
|
| EPS (Diluted) | 0.46 | 0.54 | 0.54 | 0.29 | 0.25 | 0.25 | Upgrade
|
| EPS Growth | -0.07% | 0.20% | 84.73% | 15.51% | 2.99% | -2.18% | Upgrade
|
| Free Cash Flow | -702.28 | 831.51 | 526.67 | 96.67 | 231.33 | 209.28 | Upgrade
|
| Free Cash Flow Per Share | -0.51 | 0.60 | 0.39 | 0.07 | 0.20 | 0.19 | Upgrade
|
| Dividend Per Share | 0.267 | 0.267 | 0.069 | 0.069 | 0.036 | 0.024 | Upgrade
|
| Dividend Growth | 284.29% | 284.29% | 0% | 94.94% | 49.58% | - | Upgrade
|
| Gross Margin | 43.25% | 45.28% | 43.15% | 43.63% | 55.60% | 51.19% | Upgrade
|
| Operating Margin | 30.21% | 30.95% | 28.45% | 23.51% | 26.12% | 22.74% | Upgrade
|
| Profit Margin | 29.48% | 30.20% | 27.65% | 21.26% | 22.76% | 21.74% | Upgrade
|
| Free Cash Flow Margin | -32.98% | 33.24% | 20.05% | 5.23% | 17.56% | 16.66% | Upgrade
|
| EBITDA | 782.66 | 873.47 | 819.26 | 504.05 | 397.56 | 332.86 | Upgrade
|
| EBITDA Margin | 36.76% | 34.92% | 31.19% | 27.25% | 30.18% | 26.49% | Upgrade
|
| D&A For EBITDA | 139.33 | 99.21 | 72.12 | 69.15 | 53.42 | 47.14 | Upgrade
|
| EBIT | 643.33 | 774.26 | 747.14 | 434.9 | 344.14 | 285.72 | Upgrade
|
| EBIT Margin | 30.21% | 30.95% | 28.45% | 23.51% | 26.12% | 22.74% | Upgrade
|
| Effective Tax Rate | 14.08% | 15.30% | 14.65% | 17.84% | 17.94% | 18.39% | Upgrade
|
| Revenue as Reported | 2,129 | 2,502 | 2,626 | 1,850 | 1,317 | 1,257 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.